Rhabdoid tumors: Integrating biological insights with clinical success. A report from the SMARCB1 and Rhabdoid Tumor Symposium, Paris, December 12-14, 2013

Cancer Genetics

Volumn 207, Issue 9, 2014, Pages 346-351

  Bourdeaut, Franck ^a   Chi, Susan N ^b   Frühwald, Michael C ^c  

^a INSTITUT CURIE   (France)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c Childrens Hospital Augsburg and EU RHAB Registry   (Germany)

Author keywords

ATRT; INI1; Rhabdoid; SMARCB1; SWI SNF

Indexed keywords

ALISERTIB; ARSENIC TRIOXIDE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; NUCLEIC ACID BINDING PROTEIN; PROTEIN SMARCB1; PROTEIN SWI; TRANSCRIPTION FACTOR SNF; UNCLASSIFIED DRUG; VINCRISTINE; DNA BINDING PROTEIN; NONHISTONE PROTEIN; SMARCB1 PROTEIN, HUMAN; SWI-SNF-B CHROMATIN-REMODELING COMPLEX; TRANSCRIPTION FACTOR; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ATYPICAL TERATOID RHABDOID TUMOR; CANCER PROGNOSIS; CANCER RESEARCH; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMPLEX FORMATION; FRANCE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT RHABDOID TUMOR; MOLECULAR PATHOLOGY; NEURILEMOMA; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RHABDOID TUMOR; SCHWANNOMATOSIS; BIOSYNTHESIS; CENTRAL NERVOUS SYSTEM; GENETICS; INFANT; KIDNEY; KIDNEY TUMOR; NEWBORN; PATHOLOGY; SOFT TISSUE TUMOR;

CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; HUMANS; INFANT; INFANT, NEWBORN; KIDNEY; KIDNEY NEOPLASMS; RHABDOID TUMOR; SOFT TISSUE NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84920196792     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2014.10.004     Document Type: Review

References (31)

1. Beckwith J.B., Palmer N.F. Histopathology and prognosis of Wilms tumors: results from the First National Wilms' Tumor Study. Cancer 1978, 41:1937-1948.
2. Rorke L.B., Packer R.J., Biegel J.A. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. JNeurosurg 1996, 85:56-65.
3. Versteege I., Sévenet N., Lange J., et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998, 394:203-236.
4. Biegel J.A., Zhou J.Y., Rorke L.B., et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999, 59:74-79.
5. Biegel J.A., Kalpana G., Knudsen E.S., et al. The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors. Cancer Res 2002, 62:323-328.
6. Yaniv M. Chromatin remodeling: from transcription to cancer. Cancer Genet 2014, 207:352-357.
7. Kim K.H., Roberts C.W. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. Cancer Genet 2014, 207:365-372.
8. Smith M., O'Sullivan J., Bashkar S., et al. Involvement of the SWI/SNF complex in familial meningiomatosis [abstract]. Cancer Genet 2014, 207:445.
9. Lee R.S., Stewart C., Carter S.L., et al. Aremarkably simple genome underlies highly malignant pediatric rhabdoid cancers. JClin Invest 2012, 122:2983-2988.
10. Johann P., Korshunov A., Kornelius K. CNS AT/RTs are a heterogeneous entity that comprises subgroups with distinct molecular profiles [abstract]. Cancer Genet 2014, 207:447.
11. Jagani Z., Mora-Blanco E.L., Sansam C.G., et al. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med 2010, 16:1429-1433.
12. Finetti M., Selby M., del Carpio Pons A., et al. Characterising critical pathways in malignant rhabdoid tumourigenesis: a Genome-wide analysis of primary tumours and functional genomic models [abstract]. Cancer Genet 2014, 207:447.
13. Torchia J., Picard D., Anh Kwang D., et al. Integrative genomic analyses of atypical teratoid rhabdoid tumours (ATRTs) [abstract]. Cancer Genet 2014, 207:447-448.
14. Kuwahara Y., Wei D., Song S., et al. SNF5/INI1, deficiency destabilizes the SWI/SNF complex during malignant rhabdoid tumor development [abstract]. Cancer Genet 2014, 207:445.
15. Darr J., Klochendler A., Isaac S., et al. Alterations in IGFBP7 and EGFR/AKT pathway in SMARCB1 deficient tumor cells [abstract]. Cancer Genet 2014, 207:446.
16. Richer R., Lucchesi C., Lequin D. Rhabdoid tumours of brain, liver, kidney and soft-parts: expression profiles suggest common features but different entities [abstract]. Cancer Genet 2014, 207:448.
17. Smith M.J., Wallace A.J., Bowers N.L., et al. SMARCB1 mutations in schwannomatosis and genotype correlations with rhabdoid tumors. Cancer Genet 2014, 207:373-378.
18. Hulsebos T., Kenter S., Volkmar H., et al. Expression of mutant SMARCB1 proteins in schwannomas of schwannomatosis patients [abstract]. Cancer Genet 2014, 207:450-451.
19. Vitte J., Chareyre F., Stemmer-Rachamimov A., et al. Conditional inactivation of SMARCB1 in P0 permissive mouse cells generates rhabdoid tumors in the peripheral nervous system [abstract]. Cancer Genet 2014, 207:451.
20. Han Z.H., Richer W., Lucchesi C., et al. ASMARCB1-deficient, highly penetrant brain tumour mouse model recapitulates human AT/RT [abstract]. Cancer Genet 2014, 207:451.
21. Margol A.S., Judkins A.R. Pathology and diagnosis of SMARCB1-deficient tumors. Cancer Genet 2014, 207:358-364.
22. Van Lan T., Frühwald M.C., Hasselblatt M., et al. Identifying molecular markers for the sensitive detection of residual atypical teratoid rhabdoid tumor cells. Cancer Genet 2014, 207:390-397.
23. Chakravadhanula M., Tembe W., Legendre C., et al. Detection of an ATRT brain tumor gene deletion diagnostic in circulating blood using next gen sequencing [abstract]. Cancer Genet 2014, 207:450.
24. Bhardwaj R.D., Hampton C., Ozols V., et al. Analysis of the Wnt5b signaling pathway to identify novel therapeutics for atypical teratoid rhabdoid tumors. Cancer Genet 2014, 207:451-452.
25. Kerl K., Moreno N., Holsten T., et al. Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumor cell invitro and invivo by targeting overexpressed Gli1. Cancer Genet 2014, 207:452.
26. Hu Y., Bobb D., He J., et al. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor. Cancer Genet 2014, 207:403-411. [abstract].
27. Keilhack H. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of EZH2. Cancer Genet 2014, 207:452-453.
28. Bartelheim K., Sumerauer D., Behrends U., et al. Clinical and genetic features of rhabdoid tumors of the heart registered with the European Rhabdoid Registry (EU-RHAB). Cancer Genet 2014, 207:379-383.
29. Chi S.N., Zimmerman M.A., Yao X., et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. JClin Oncol 2009, 27:385-389.
30. Wetmore C., Bendel A., Gajjar A. Activity of alisertib (MLN8237) as single agent in recurrent atypical teratoid rhabdoid tumor (AT/RT) in four children: a single patient treatment plan pilot study. Cancer Genet 2014, 207:453.
31. Fay-McClymont T., Lafay-Cousin L., Janzen L., et al. Neurocognitive evaluation of long term survivor's patients with AT/RT. Cancer Genet 2014, 207:454.